NJ Bio, Inc., is thrilled to announce its participation in several prestigious conferences this year. Starting the year with a strong presence, NJ Bio will be participating in the renowned AACR Annual Meeting, a premier event in cancer research and medicine. Scheduled to take place from April 5th to April 10th, 2024, this conference promises to attract top professionals in the field. NJ Bio’s team will be sharing their expertise in antibody drug conjugates (ADCs) and targeted therapies for cancer, with a dedicated booth to engage with fellow enthusiasts. Notably, the company will also present their work on siteDAR©, an innovative tool designed for comprehensive ADC characterization, offering potential for the development of next-generation ADCs.
Following the AACR Annual Meeting, NJ Bio will be actively participating in the BIO International Convention 2024, recognized as one of the largest gatherings in the biotechnology sector. With an anticipated attendance of over 20,000 industry experts, the event will be held at the San Diego Convention Center from June 3rd to June 6th, 2024. The organization looks forward to connecting with science enthusiasts and exchanging insights gained from the latest advancements in the ADC space.
Rounding off the year on a high note, NJ Bio eagerly anticipates its involvement in the 15th World ADC Conference, slated to take place in San Diego from November 4th to November 7th, 2024. Organized by HansonWade, this flagship event is renowned for its distinguished speakers and the participation of pioneers in the field of ADC research. The CRO/ CDMO plans to present its latest work and contribute to the dynamic discussions surrounding ADCs, promising an enriching experience for all attendees.
With its participation in these esteemed conferences, NJ Bio reaffirms its commitment to fostering knowledge exchange to advance ADC research and work towards developing effective next-generation ADCs for cancer treatment.
